cyrilzakka/clinical-trials huggingface dataset:
The Effect of Postpartum Pelvic Floor Rehabilitation in Prevention and Treatment of Pelvic Floor Dysfunction

Pregnancy and childbirth are considered as risk periods for injuries to the pelvic floor and development of pelvic floor dysfunction. This may leed to devastating loss of function and quality of life.The aim of this study is to evaluate the effect of postpartum pelvic floor muscle training with the device "PHENIX Neuromuscular Stimulation Therapy Systems" on the recovery of pelvic floor function for primiparous women.


Eligibility Criteria:
Inclusion Criteria:

* primiparous delivery
* term delivery
* single childbirth
* aged from 18-50yrs

Exclusion Criteria:

* urinary incontinence before pregnancy
* fecal incontinence before pregnancy
* organ prolapse before pregnancy
* history of childbirth or induced labor with pregnancy more than 28 weeks
* multiparity
* newborn weight less than 2500 grams or more than 4000 grams
* precipitate labor
* complication of pregnancy
* asthma
* long-term abdominal pressure(chronic cough\>1 month,chronic constipation)
* diabetes
* sciatica
* history of pelvic operation
Evaluation of the Safety of LipiodolⓇ Embolization in Symptomatic Digital Osteoarthritis Refractory to Conventional Treatment

The goal of this clinical trial is to evaluate the safety of arterial embolization using Lipiodol® in patients with symptomatic hand osteoarthritis refractory to conventional treatment. It will also learn about the efficacy of arterial embolization with Lipiodol® in reducing pain and improving hand function.

The main questions it aims to answer are:

* What are the side effects and complications associated with the Lipiodol® arterial embolization procedure?
* Does arterial embolization reduce pain intensity and improve hand function?

Researchers will evaluate patients over a 6-month period to assess the safety of Lipiodol® embolization and its impact on joint pain, swelling, and functional capacity. Participants will:

* Undergo arterial embolization with Lipiodol®
* Participate in regular follow-ups to monitor pain relief, hand function, and any side effects
* Have imaging studies to assess changes in joint vascularisation and damage


Eligibility Criteria:
Inclusion Criteria:

* Patients aged ≥ 40 years.
* Osteoarthritis of the hand according to American College of Rheumatology criteria 1990
* Osteoarthritis affecting at least two proximal and/or distal interphalangeal joints with a radiological Kellgren-Lawrence stage ≥ 2.
* Symptomatic osteoarthritis within the last 3 months.
* Visual analogue pain scale of the hand to be treated ≥ 40/100 mm (most painful hand).
* Inadequate response, adverse effects and/or contraindication to NSAIDs and non-opioid analgesics.
* Patient affiliated to french social security or a similar health assurance.

Exclusion Criteria:

* History of allergy to iodinated contrast media, LipiodolⓇ or poppies.
* Vasomotor disorders (Raynaud\&#39;s syndrome, scleroderma, acrocyanosis).
* Stenosis (\&gt;50%) or known atheromatous arterial occlusion of the upper limbs.
* Obliterative arterial disease of the lower limbs at the critical ischaemia stage.
* Severe to end-stage chronic renal insufficiency (glomerular filtration rate \&lt; 30ml/min/1.73m2), dialysis or renal transplant.
* Arteritis such as thromboangiitis obliterans disease or other diseases
* Previous thrombosis/dissection of the radial artery.
* Chronic inflammatory rheumatic disease (rheumatoid arthritis, psoriatic arthritis, microcrystalline arthritis, etc.).
* Known hyperthyroidism or large multinodular goiter.
* Traumatic lesions, haemorrhages or chronic bleeding in the hand (not completely resolved within 3 months of the start of the lesion) requiring embolisation.
* Pregnant or breast-feeding.
* Patients covered by articles L1121-5 to L1121-8 of the French Public Health Code and/or who do not speak French.
* Patients in a period of exclusion or in the course of another interventional clinical trial.
The Real Distribution of Microbiota Along the Colon Using a Novel Device Along the Colon Using a Novel Device

The human microbiota forms a highly complex ecosystem with its host, consisting of hundreds of different species of microorganisms, the majority of which have not yet been cultured. With the recent advent of small subunit rRNA (SSU rRNA) gene sequencing technology, it is estimated that the number of specific gastrointestinal tract phylotypes is more than 1800. Sampling techniques might constitute a major confounder in the read-out of highly sensitive techniques such as SSU-DNA analysis.

It is not properly established whether there is a difference in distribution of luminal bacteria or mucosa adherent bacteria proximal or distal in the colon. In addition, 'bowel lavage' before endoscopy might result in a disturbance of the microbiota in the bowel. For this proof of concept study a novel device capable of taking 'protected' biopsies has been designed.

We hypothesize that the distribution of mucosal and luminal microbiota changes from proximal to distal in the colon, and by taking 'protected biopsies' there will be the opportunity to show the real distribution of microbiota according to the localisation in the colon.

Furthermore, we hypothesize that microbial diversity will differ after bowel lavage.

We hypothesize that the distribution of mucosal and luminal microbiota changes from proximal to distal in the colon, and by taking 'protected biopsies' there will be the opportunity to show the real distribution of microbiota according to the localisation in the colon.

Eligibility Criteria:
* Inclusion Criteria:

  * Ill prepared colon during index colonoscopy or sigmoidoscopy: Boston scale \<3
* Sufficient indication to perform colonoscopy again

Exclusion Criteria:

* Inability to give informed consent
* Life expectancy \< 12 months
* Use of combination of two platelet aggregation inhibitors
* Mandatory use of anti-coagulatory medication
* Known history of hemostatic disorder
* Use of systemic antibiotics in preceding 6 weeks
* Use of probiotic or prebiotic treatment in preceding 6 weeks
* Positive stool cultures for common enteric pathogens (Salmonella, Shigella, Yersinia, Campylobacter, enteropathogenic e coli)
* History of surgery:

  * Resection of any part of the colon or Ileocoecal resection
  * Presence of an ileo- or colostoma
The Angioma's Treatment Evaluation With Laser Doppler Imaging (LDI)

Based on the Doppler effect, Laser Doppler Imaging (LDI) uses the interaction of light with moving erythrocytes to visualize perfusion in the microcirculatory system.

The new device to be used in this study have been adapted specifically for the application, facilitating its use in clinic. It has been designed to take a standard white light image of the area under inspection simultaneously with the perfusion image to facilitate clinical assessment.

Port-wine stain (PWS) birthmarks are congenital, low-flow vascular malformations of the skin found in approximately 0.3% of children. They are commonly found on the face and neck and may cause serious psychological consequences.

Lasers are the modality of choice for the treatment of PWS birthmarks. The use of PDL is very effective in PWS in closing the blood vessels and diminishing therefore the redness of the skin. Repeated laser treatment is necessary to achieve the desired clinical outcome.

Actually, the efficacy of the treatment of PWS by the laser is obtained by clinical inspection and digital photography.

By measuring the activity and intensity of the microcirculation present in and under the skin, the Laser-Doppler (LDI) will be capable of measuring the effect of Pulsed dye laser (PDL) treatment for port-wine stains.


Eligibility Criteria:
Inclusion Criteria:

* children aged 12 months to 6 years old
* port-wine stains (PWS)
* phototype's skin I, II or III

Exclusion Criteria:

* phototype's skin IV, V or VI
* prior treatment with laser
* contraindication of general anesthesia
* refusal from the parents
Study to Evaluate Efficacy and Safety of S303 Treated Red Blood Cells (RBCs)in Subjects With Thalassemia Major Requiring Chronic RBC Transfusion

To evaluate the efficacy and safety of S 303 treated red blood cells (RBCs) in subjects who require chronic transfusion support due to thalassemia major.

To evaluate the efficacy and safety of S 303 treated red blood cells (RBCs) in subjects who require chronic transfusion support due to thalassemia major.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥10 years, of either gender
* Diagnosed with thalassemia major and currently participating in a chronic transfusion program
* At least a one year history of chronic RBC transfusion support with a stable transfusion requirement (per treating physician)
* Intervals of at least 14 days between RBC transfusions
* All RBC components are given on one day for each transfusion episode
* Negative direct antiglobulin tests (DAT)
* Stable iron chelation regimen
* Available for measurement of hemoglobin level at one hour post transfusion
* Signed and dated informed consent form

Exclusion Criteria:

* Baseline antibody specific to S 303 treated RBC (positive test, as defined in Section 8.4.1)
* Evidence of splenic hyper function defined as a transfusion requirement \>180 cc/kg/year (at 100% hematocrit)
* Splenic enlargement: spleen palpable ≥4 cm below costal margin OR ≥18 cm in longitudinal diameter by ultrasound (chosen at the Investigator's discretion according to the data available with ultrasound data being preferable)
* Any subject for whom a transition in the number of RBC units transfused is anticipated within 12 months of study entry due to growth of the subject (e.g. a transition from 1 RBC component per transfusion cycle to 2 OR a transition from 2 to 3 is anticipated based on weight change alone)
* Alloimmunization to high frequency blood group antigens to the extent that the ready provision of compatible blood may not be feasible for the study (alloimmunization alone is not an automatic exclusion)
* Current specialized treatment with washed or frozen RBC
* Requirement for gamma irradiated RBC components (would present blinding difficulty due to blood component labeling regulations
* Treatment with any medication that is known to adversely affect RBC viability
* HIV infection (defined as RNA positive)
* HCV (hepatitis C)infection (defined as RNA positive) if treated with concomitant medications known to suppress the bone marrow
* Pregnant or breast feeding female, or female of child bearing potential not using a medically approved form of contraception
* Acute or chronic medical disorder other than thalassemia that, in the opinion of the Investigator or medical monitor, may prevent the subject from completing participation in the study
* Participation in another clinical study, either concurrently or within the previous 28 days, in which the study drug or device may influence red blood cell viability
Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

The purpose of the study is to compare the effect in blood sugar control between Lantus and twice daily intermediate acting insulins (NPH or Lente) when used as the basal insulin in a multiple daily injection setting with fast acting insulin (Lispro)


Eligibility Criteria:
Inclusion Criteria:

* Type 1 diabetes treated with insulin only for at least 1 year,
* with a Tanner stage of ≥ 2,
* had evidence of decreased insulin secretory capacity (fasting C-peptide concentration ≤0.5 mmol/L) and 7.0%≤A1c≤9.5% at screening.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Melatonin Studies of Totally Blind Children

The purpose of this study is to learn more about abnormal body rhythms in blind boys and girls that keep them from falling asleep at bed-time or cause them difficulty staying alert during the day. The investigators hope to learn if there are any differences between the body rhythms of girls and boys. The investigators also want to investigate whether age or puberty have an effect on body rhythms.

Subjects will be asked to collect saliva samples in their home hourly throughout the daytime, approximately every 2 weeks. Subjects may be monitored for up to a year, after which they will be discontinued from the study. If subjects are found to be naturally entrained to the 24-hour day, they will be monitored longitudinally for changes. Subjects will be discontinued after their monitoring period is over or after an entrained status has been confirmed. While no specific time commitment is required, we hope most subjects will participant for 4 months - 2 years.

Eligibility Criteria:
Inclusion Criteria:

* Totally blind
* Between 5-8 yrs or 17-20 yrs of age

Exclusion Criteria:

* Pregnancy
* Light perception
* Low melatonin production
* Taking melatonin
* Co-morbid medical disorders (such as seizure disorders)
Light Therapy to Treat Depression in Pediatric Stem Cell Therapy Recipients

The participants are being asked to be in this clinical trial, a type of research study, because the participants are going to have a hematopoietic stem cell transplant (HSCT) in the near future. Participants that get HSCT's often get depression and/or suffer from depressive symptoms, tiredness, and sleep disturbances.

Primary Objective

To evaluate the efficacy of BL therapy for the treatment of depression in children and adolescents undergoing hematopoietic stem cell transplant.

Secondary Objectives

* To evaluate the temporal effect and magnitude of BL vs. DL therapy on depression in pediatric patients undergoing HSCT.
* To evaluate the efficacy of BL therapy for the treatment of fatigue in children and adolescents undergoing hematopoietic stem cell transplant.
* To evaluate the response of BL therapy versus DL on sleep quality.

Exploratory Objectives

* To compare incidence of positive delirium screenings between those receiving BL therapy versus DL
* To evaluate participant and caregiver perceptions of the acceptability, ease of use, and risks/benefits of the use of Light Therapy Glasses during HSCT utilizing qualitative interviews.

If you decide to be in this study, you will be asked to:

* Complete some surveys before the study begins
* Take more surveys for about 4 weeks
* Wear light therapy glasses for about 30 minutes each day for about 4 weeks
* Wear a wrist monitor every day and night for the 1st and last week of the study to record your motion and sleeping habits.
* Keep a ''sleep diary" where you will mark the times that you sleep while wearing the wrist monitor.
* Complete an optional interview at the end of the study.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥8 to \<18 years of age at the time of enrollment
* Allogeneic HSCT planned to occur between 7 and 10 days in the future from recruitment
* Patient and/or primary caregiver reads and writes in English or Spanish
* Participant/guardian is willing to sign informed consent
* Optional interview participants must be English speaking
* Baseline self-report of depressive symptoms on the PROMIS® Pediatric Depressive Symptoms v3.0 (PROMIS-PedDepSx) ≥ 55

Exclusion Criteria:

* Taking photosensitizing medications
* Total blindness / complete lack of light perception bilaterally
* Significant physiological or psychological impairment that interferes with participation
* Any patient that, in the opinion of the primary investigator is not appropriate for the study
* Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
* Non-English-speaking participants will not be eligible for the optional qualitative interview
* Baseline self-report of depressive symptoms on the PROMIS® Pediatric Depressive Symptoms v3.0 (PROMIS-PedDepSx) \< 55
Neurotrack Virtual Cognitive Health Study

The Neurotrack Virtual Cognitive Health Study is a 12-month long, prospective study that aims to evaluate the impact of the Neurotrack Virtual Cognitive Health Coaching Program on cognitive ability, anxiety and depression, and lifestyle behaviors for individuals who show signs of subjective cognitive decline.


Eligibility Criteria:
Inclusion Criteria:

* Ages 60-75
* Individuals who show signs of subjective cognitive decline (assessed by scoring ≥ 1 on the Subjective Cognitive Decline \[Short Form\] Questionnaire and endorsing the Personal Worry Item on the questionnaire)
* Have the ability to make and receive phone calls
* Have the ability to send and receive text messages
* Access to a desktop computer, video-teleconferencing and reliable internet connection
* Motivated to use a daily coaching program

Exclusion Criteria:

* Significant history of mental illness, substance abuse, learning disability, or neurologic conditions
* History of dementia
* Ophthalmologic/visual problems that prevent individual from viewing a computer screen at a normal distance (e.g., legal blindness, detached retinas, occlusive cataracts)
* Currently participating in a formal cognitive-training coaching program
* Currently pregnant
Comparison of Analgesic Effect and Postoperative Recovery of SAPB Combined With ESPB and TPB After Thoracoscopic Surgery

After thoracoscopic surgery, patients still face moderate to severe pain. How to effectively control pain and promote postoperative recovery of patients is a challenging problem. Thoracic paraspinal block is effective in controlling pain after thoracoscopic surgery, but it also carries the risk of difficulty in operation and puncture of the pleura. In recent years, erector spinal plane block and serratus anterior plane block have been used for postoperative analgesia after thoracoscopic surgery. The purpose of this study was to explore whether erector spinal plane combined with serratus anterior plane block can replace thoracic paravertebral block and provide a more complete analgesia after thoracoscopic surgery. Therefore, this study is of great clinical significance.

In a double-blind randomized controlled study, investigators allocated 92 patients undergoing VATS to either SAPB Combined With ESPB or TPB, with both groups receiving otherwise standardized treatment, including multimodal analgesia. The primary outcome was 24-hr opioid consumption. Secondary outcomes included the number of survival analgesia at 1, 2, 4, 8, and 24 hours postoperatively ,VAS scores was assessed during resting and coughing statuses at 1, 2, 4, 8, and 24 hours postoperatively, pulmonary function indexes before and 1, 4, 24 hours after surgery , QOR-15 scores before and 24 hours after surgery, postoperative complications and recovery time nodes drainage tube removal time, discharge time.

Eligibility Criteria:
Inclusion Criteria:

1. American ASA Grade I-III;
2. Age: 18 \~ 70 years old;

3 BMI 19 \~ 28kg/m2;

4. Patients with elective thoracoscopic partial pneumonectomy under general anesthesia;

5 Informed Consent has been signed.

Exclusion Criteria:

1. Use opioid analgesics on a daily basis or have a history of opioid abuse;
2. History of ipsilateral thoracotomy;
3. Allergic to any of the drugs used in the study, or have a history of drug allergy;
4. Mental or nervous system diseases, motor or sensory deficits;

5 there is coagulation dysfunction;

6. Cognitive dysfunction, unable to cooperate with research;

7. Severe renal, hepatic or cardiac dysfunction;

8. Chest wall and spine trauma, infection, deformity and other cases where nerve block cannot be performed;

9. Participated in other clinical trials within the 3 months prior to study inclusion;

10. Investigators consider other reasons unsuitable for clinical trial participants;

11. Patients refuse to participate.
Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients With Liver Failure Caused by Hepatitis B Virus (HBV)

Allogeneic Bone Marrow Mesenchymal Stem Cells Transplantation in Patients with Liver Failure Caused by hepatitis B virus (HBV)


Eligibility Criteria:
Inclusion Criteria:

* Liver failure caused by HBV
* Model for End-Stage Liver Disease (MELD) \< 30

Exclusion Criteria:

* Liver Failure caused by other reasons, such as autoimmune diseases, alcohol, drug and so on.
* History of moderate to severe hepatic encephalopathy or variceal bleeding during the last two months before enrollment.
* Severe problems in other vital organs (e.g.the heart,renal or lungs).
* Tumor on ultrasonography, CT or MRI examination.
* Pregnant or lactating women.
* HIV infection.
Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection

Sepsis is the leading cause of death in intensive care units and a major public health concern in the world. Heparin, a widely used anticoagulant medicine to prevent or treat thrombotic disorders, has been demonstrated to prevent organ damage and lethality in experimental sepsis models. However, the efficacy of heparin in the treatment of clinical sepsis is not consistent. Caspase-11, a cytosolic receptor of LPS, triggers lethal immune responses in sepsis. Recently, we have revealed that heparin prevents cytosolic delivery of LPS and caspase-11 activation in sepsis through inhibiting the heparanase-mediated glycocalyx degradation and the HMGB1- LPS interaction, which is independent of its anticoagulant properties. In our study, it is found that heparin treatment could prevent lethal responses in endotoxemia or Gram-negative sepsis, while caspase-11 deficiency or heparin treatment failed to confer protection against sepsis caused by Staphylococcus aureus, a type of Gram-positive bacterium. It is probably that other pathogens such as Gram-positive bacteria might cause death through mechanisms distinct from that of Gram-negative bacteria. Peptidoglycan, a cell-wall component of Gram-positive bacteria, can cause DIC and impair survival in primates by activating both extrinsic and intrinsic coagulation pathways, which might not be targeted by heparin. We speculate that the discrepancy between the previous clinical trials of heparin might be due to the difference in infected pathogens. Thus, stratification of patients based on the type of invading pathogens might improve the therapeutic efficiency of heparin in sepsis, and this merits future investigations.

In clinical patients, the major pathogens of sepsis caused by abdominal infection are mostly Gram-negative bacterium. Therefore, aim of this study is to determine effects of low dose unfractionated heparin for treatment of sepsis caused by abdominal infection.

Eligibility Criteria:
Inclusion Criteria:

Patients will be eligible for inclusion if all of the inclusion criteria are met:

1.Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of Intensive Care Medicine (ESICM), and the infection site is from abdomen 2.18≤ age ≤75years 3.obtain informed consent

Exclusion Criteria:

1. The primary site of infection is from other parts (such as lungs, intracranial, etc.) except abdomen
2. Diagnosis of sepsis for more than 48 hour
3. Pregnant and lactating women
4. Severe primary disease including unrespectable tumours, blood diseases and Human Immunodeficiency Virus (HIV);
5. Have a known or suspected adverse reaction to UFH including HIT
6. Have bleeding or high risk for bleeding
7. Have an indication for therapeutic anticoagulation or have taken anticoagulants within 7 days
8. Use of an immunosuppressant or having an organ transplant within the previous 6 months
9. Participating in other clinical trials in the previous 30 days
10. Have received cardiopulmonary resuscitation within 7 days
11. Have terminal illness with a life expectancy of less than 28 days